Roger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, Michael Hughes, Bryan S Nelson, Aischa Niesar, Molly Pretorius Holme, Kathleen M Powis, Maureen Sakoi, Oganne Batlang, Sikhulile Moyo, Terence Mohammed, Comfort Maphorisa, Kara Bennett, Zixin Hu, Francoise Giguel, Jacqueline D Reeves, Michael A Reeves, Ce Gao, Xu Yu, Margaret E Ackerman, Adrian McDermott, Marlene Cooper, Marina Caskey, Lucio Gama, Patrick Jean-Philippe, Dwight E Yin, Edmund V Capparelli, Shahin Lockman, Joseph Makhema, Daniel R Kuritzkes, Mathias Lichterfeld
Broadly neutralizing antibodies (bNAbs) may provide an alternative to standard antiretroviral treatment (ART) for controlling HIV-1 replication and may have immunotherapeutic effects against HIV-1 reservoirs. We conducted a prospective clinical trial with two HIV-1 bNAbs (VRC01LS and 10-1074) in children ( n = 25) who had previously initiated small-molecule ART treatment before 7 days of age and who continued treatment for at least 96 weeks. Both bNAbs were dosed intravenously every 4 weeks, overlapping with ART for at least 8 weeks and then continued for up to 24 weeks or until detectable viremia of HIV-1 RNA rose above 400 copies per milliliter in the absence of ART...
July 5, 2023: Science Translational Medicine